1. Arock M, Valent P. Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol . 2010;3:497-516.
2. Pardanani A. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management. Am J Hematol. 2013;88:612-624.
3. Orfao A, Garcia-Montero AC, Sanchez L, et al. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol. 2007;138:12-30.
4. Yanagihori H, Oyama N, Nakamura K, et al. c-KIT mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation. J Mol Diagn. 2005;7:252-257.
5. Bodemer C, Hermine O, Palmérini F, et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol. 2010;130:804-815.
6. Kettelhut BV, Metcalfe DD. Pediatric mastocytosis. Ann Allergy. 1994;73:197-202; quiz 202-207.
7. Longley J, Duffy TP, Kohn S. The mast cell and mast cell disease. J Am Acad Dermatol. 1995;32:545-561; quiz 562-564.
8. Sotlar K, Cerny-Reiterer S, Petat-Dutter K, et al. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. Mod Pathol. 2011;24:585-595.
9. Blatt K, Cerny-Reiterer S, Schwaab J, et al. Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis [published online October 20, 2015]. Blood. 2015;126:2832-2841.
10. Kiszewski AE, Duran-Mckinster C, Orozco-Covarrubias L, et al. Cutaneous mastocytosis in children: a clinical analysis of 71 cases. J Eur Acad Dermatol Venereol. 2004;18:285-290.
11. Akoglu G, Erkin G, Cakir B, et al. Cutaneous mastocytosis: demographic aspects and clinical features of 55 patients. J Eur Acad Dermatol Venereol. 2006;20:969-973.
12. Sarkany RP, Monk BE, Handfield-Jones SE. Telangiectasia macularis eruptiva perstans: a case report and review of the literature. Clin Exp Dermatol. 1998;23:38-39.
13. Lack EE, Worsham GF, Callihan MD, et al. Granular cell tumor: a clinicopathologic study of 110 patients. J Surg Oncol. 1980;13:301-316.
14. Buley ID, Gatter KC, Kelly PM, et al. Granular cell tumours revisited. an immunohistological and ultrastructural study. Histopathology. 1988;12:263-274.
15. Penneys NS, Adachi K, Ziegels-Weissman J, et al. Granular cell tumors of the skin contain myelin basic protein. Arch Pathol Lab Med. 1983;107:302-303.
16. Modlin RL, Gottlieb B, Taylor C, et al. Identification of cells lining pseudovascular spaces of benign pigmented nevi. Am J Dermatopathol. 1984;(suppl 6):25-29.
17. Fullen DR, Reed JA, Finnerty B, et al. S100A6 preferentially labels type C nevus cells and nevic corpuscles: additional support for Schwannian differentiation of intradermal nevi. J Cutan Pathol. 2001;28:393-399.
18. Newman B, Hu W, Nigro K, et al. Aggressive histiocytic disorders that can involve the skin. J Am Acad Dermatol. 2007;56:302-316.
19. Weedon D. Cutaneous infiltrates—non-lymphoid. In: Weedon D, ed. Weedon’s Skin Pathology. 3rd ed. Amsterdam, Netherlands: Elsevier; 2010:937-970.
20. Harrist TJ, Bhan AK, Murphy GF, et al. Histiocytosis-X: in situ characterization of cutaneous infiltrates with monoclonal antibodies. Am J Clin Pathol. 1983;79:294-300.
21. Lau SK, Chu PG, Weiss LM. Immunohistochemical expression of langerin in Langerhans cell histiocytosis and non-Langerhans cell histiocytic disorders. Am J Surg Pathol. 2008;32:615-619.
22. Lesher JL Jr, Allen BS. Multicentric reticulohistiocytosis. J Am Acad Dermatol. 1984;11:713-723.
23. Heathcote JG, Guenther LC, Wallace AC. Multicentric reticulohistiocytosis: a report of a case and a review of the pathology. Pathology. 1985;17:601-608.
